This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2023 Oct 5;142(14):1178-1180.

doi: 10.1182/blood.2023021311.

Birtamimab: a new amyloidosis treatment?

Antoine Huart¹

Affiliations

PMID: 37796521
DOI: 10.1182/blood.2023021311

Free article

Editorial

Birtamimab: a new amyloidosis treatment?

Antoine Huart. Blood. 2023.

Free article

. 2023 Oct 5;142(14):1178-1180.

doi: 10.1182/blood.2023021311.

Author

Antoine Huart¹

Affiliation

¹ University Hospital of Toulouse.

PMID: 37796521
DOI: 10.1182/blood.2023021311

No abstract available

PubMed Disclaimer

Comment on

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.
Gertz MA, Cohen AD, Comenzo RL, Kastritis E, Landau HJ, Libby EN, Liedtke M, Sanchorawala V, Schönland S, Wechalekar A, Zonder JA, Palladini G, Walling J, Guthrie S, Nie C, Karp C, Jin Y, Kinney GG, Merlini G. Gertz MA, et al. Blood. 2023 Oct 5;142(14):1208-1218. doi: 10.1182/blood.2022019406. Blood. 2023. PMID: 37366170 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems